20-023 - Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)Status: open
|S1900C - A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)|
Treatment for Lung Cancer
This is an investigational study of two drugs (talazoparib and avelumab) used in combination to treat a type of lung cancer (non-squamous non-small cell lung cancer [NSCLC]) in patients whose disease has progressed. The goal of this study is to target a mutation that can occur within the cancer cells of some non-squamous NSCLC patients.
SponsorsThis trial is sponsored by National Cancer Institute (NCI).
Interested in Clinical Trial?
Providers Associated With This Trial
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
- Moh'd Khushman, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology